Aardvark Therapeutics (NASDAQ:AARD) Issues Quarterly Earnings Results

Aardvark Therapeutics (NASDAQ:AARD) released its quarterly earnings data on Monday. The company reported ($0.81) earnings per share for the quarter, FiscalAI reports.

Aardvark Therapeutics Price Performance

NASDAQ:AARD remained flat at $4.07 during midday trading on Monday. 207,932 shares of the company were exchanged, compared to its average volume of 287,026. The firm has a market capitalization of $88.60 million and a PE ratio of -1.92. Aardvark Therapeutics has a 1-year low of $4.01 and a 1-year high of $17.94. The business has a fifty day moving average price of $11.04 and a two-hundred day moving average price of $11.75.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on AARD. HC Wainwright reissued a “neutral” rating on shares of Aardvark Therapeutics in a research note on Monday, March 2nd. Morgan Stanley reiterated an “equal weight” rating and set a $7.00 price target (down from $29.00) on shares of Aardvark Therapeutics in a report on Monday, March 2nd. Oppenheimer dropped their price target on Aardvark Therapeutics from $35.00 to $21.00 and set an “outperform” rating on the stock in a research report on Monday, March 2nd. William Blair assumed coverage on Aardvark Therapeutics in a research note on Friday, December 12th. They issued an “outperform” rating for the company. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Aardvark Therapeutics in a research report on Monday, December 29th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $25.09.

Institutional Trading of Aardvark Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of AARD. SymBiosis Capital Partners LLC acquired a new stake in shares of Aardvark Therapeutics in the 4th quarter valued at $6,255,000. Millennium Management LLC acquired a new stake in shares of Aardvark Therapeutics during the 3rd quarter worth about $4,248,000. Cresset Asset Management LLC bought a new position in Aardvark Therapeutics during the 3rd quarter valued at about $1,951,000. Geode Capital Management LLC lifted its holdings in Aardvark Therapeutics by 53.5% during the 4th quarter. Geode Capital Management LLC now owns 297,865 shares of the company’s stock valued at $3,910,000 after purchasing an additional 103,830 shares during the last quarter. Finally, Vanguard Group Inc. boosted its position in Aardvark Therapeutics by 20.6% in the third quarter. Vanguard Group Inc. now owns 555,721 shares of the company’s stock valued at $7,386,000 after buying an additional 94,744 shares in the last quarter.

About Aardvark Therapeutics

Aardvark Therapeutics, Inc is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of small-molecule modulators of the retinoic acid receptor–related orphan receptor gamma (RORγ). RORγ plays a central role in T-helper 17 (Th17) cell differentiation and inflammatory processes. By targeting this transcription factor, Aardvark aims to address a range of autoimmune and immune-mediated diseases.

The company’s lead programs consist of selective RORγ inverse agonists designed to suppress pathogenic Th17-driven responses in conditions such as psoriasis, inflammatory bowel disease and other chronic inflammatory disorders.